EGFR and non-small cell lung carcinoma: Furthermore, our study explores the potential of a flow cytometry-based analysis of pre-treatment whole blood lymphocyte subsets in predicting treatment outcomes with Chemo+ICIs for patients with advanced NSCLC, irrespective of treatment history and EGFR mutation status.